This repository describes the comprenhensive molecular assessment of the efficacy and mechanisms of felzartamab, a CD38 monoclonal antibody, for use as therapy to treat antibody-mediated rejection in kidney allografts. 

This is part of the clinical trial: Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection - A Phase 2 Pilot Trial
(https://clinicaltrials.gov/study/NCT05021484)

A friendly user guide to the analyses carried out in this project can be found here: [GitHub Wiki](https://tsi-ptg.github.io/CD38-effect-of-treatment/)
